292 related articles for article (PubMed ID: 38043802)
21. Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
Salas MQ; Alfaro-Moya T; Atenafu EG; Datt Law A; Lam W; Pasic I; Novitzky-Basso I; Santos Carreira A; Chen C; Michelis FV; Gerbitz A; Howard Lipton J; Kim DDH; Kumar R; Mattsson J; Viswabandya A
Transplant Cell Ther; 2024 May; 30(5):536.e1-536.e13. PubMed ID: 38281592
[TBL] [Abstract][Full Text] [Related]
22. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide.
Rappazzo KC; Zahurak M; Bettinotti M; Ali SA; Ambinder AJ; Bolaños-Meade J; Borrello I; Dezern AE; Gladstone D; Gocke C; Fuchs E; Huff CA; Imus PH; Jain T; Luznik L; Rahmat L; Swinnen LJ; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2021 Nov; 27(11):909.e1-909.e6. PubMed ID: 34425261
[TBL] [Abstract][Full Text] [Related]
23. Risk of Cytomegalovirus Infection with Post-Transplantation Cyclophosphamide in Haploidentical and HLA-Matched Unrelated Donor Transplantation.
Jamy O; Hebert C; Dunn-Valadez S; Magnusson T; Watts N; McGwin G; Saad A
Transplant Cell Ther; 2022 Apr; 28(4):213.e1-213.e6. PubMed ID: 35074557
[TBL] [Abstract][Full Text] [Related]
24. Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari L; Balaguer-Roselló A; Montoro J; Greco R; Hernani R; Lupo-Stanghellini MT; Villalba M; Giglio F; Facal A; Lorentino F; Guerreiro M; Bruno A; Pérez A; Xue E; Clerici D; Piemontese S; Piñana JL; Sanz MÁ; Solano C; de la Rubia J; Ciceri F; Peccatori J; Sanz J
Bone Marrow Transplant; 2022 Sep; 57(9):1389-1398. PubMed ID: 35680995
[TBL] [Abstract][Full Text] [Related]
25. Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma.
Nakaya Y; Nakamae H; Nishikubo M; Kondo E; Fukuda T; Hiramoto N; Mori Y; Nagafuji K; Eto T; Onishi Y; Uchida N; Ishikawa J; Matsuoka KI; Yui S; Takase K; Kawakita T; Kanda J; Ichinohe T; Atsuta Y; Kako S
Bone Marrow Transplant; 2024 May; 59(5):630-636. PubMed ID: 38355911
[TBL] [Abstract][Full Text] [Related]
26. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT).
Ortí G; Gras L; Koster L; Kulagin A; Byrne J; Apperley JF; Halaburda K; Blau IW; Clark A; Kröger N; Griskevicius L; Carlson K; Collin M; Bloor A; Raiola AM; Blaise D; Aljurf M; López-Corral L; Sakellari I; Beguin Y; Wrobel T; de Rosa L; de Lavallade H; Hayden PJ; McLornan D; Chalandon Y; Yakoub-Agha I
Transplant Cell Ther; 2024 Jan; 30(1):93.e1-93.e12. PubMed ID: 37783337
[TBL] [Abstract][Full Text] [Related]
27. PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma-A Matched-Pair Analysis.
Haebe S; Fraccaroli A; Stauffer E; Prevalsek D; Zoellner AK; Drolle H; Stemmler HJ; Dreyling M; von Bergwelt-Baildon M; Tischer J
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958420
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Swoboda R; Kulagin A; Labussière-Wallet H; Rovira M; Blaise D; Vydra J; Yakoub-Agha I; Choi G; Reményi P; Koc Y; Sanz J; Ciceri F; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):552-557. PubMed ID: 36823454
[TBL] [Abstract][Full Text] [Related]
29. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM
Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648
[TBL] [Abstract][Full Text] [Related]
30. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A; Jorge S; Suárez-Lledó M; Pereira A; Gutiérrez-García G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Transplant Cell Ther; 2021 Jul; 27(7):619.e1-619.e8. PubMed ID: 33895157
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
[TBL] [Abstract][Full Text] [Related]
32. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
Sanz J; Galimard JE; Labopin M; Afanasyev B; Sergeevich MI; Angelucci E; Kröger N; Koc Y; Ciceri F; Diez-Martin JL; Arat M; Sica S; Rovira M; Aljurf M; Tischer J; Savani B; Ruggeri A; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):84. PubMed ID: 34049582
[TBL] [Abstract][Full Text] [Related]
33. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation.
Mehta RS; Saliba RM; Rondon G; Al-Atrash G; Bashir Q; Hosing CM; Kebriaei P; Khouri I; Nieto Y; Oran B; Popat UR; Qazilbash MH; Ramdial J; Srour SA; Champlin RE; Rezvani K; Shpall EJ; Alousi AM
Transplant Cell Ther; 2022 Oct; 28(10):695.e1-695.e10. PubMed ID: 35902049
[TBL] [Abstract][Full Text] [Related]
34. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation.
Bailén R; Kwon M; Pascual-Cascón MJ; Ferrà C; Sanz J; Gallardo-Morillo A; García-Sola A; Torrent A; Jiménez-Lorenzo MJ; Piñana JL; Montoro J; Oarbeascoa G; Dorado N; Gómez-Centurión I; Muñoz C; Martínez-Laperche C; Anguita J; Buño I; Díez-Martín JL;
Ann Hematol; 2021 Feb; 100(2):541-553. PubMed ID: 33140137
[TBL] [Abstract][Full Text] [Related]
35. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
36. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant.
Iqbal M; Nieto FAM; Brannick KM; Li Z; Murthy H; Foran J; Roy V; Kharfan-Dabaja MA; Ayala E
Transplant Cell Ther; 2023 May; 29(5):327.e1-327.e9. PubMed ID: 36758832
[TBL] [Abstract][Full Text] [Related]
37. Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors.
George B; Pn N; Devasia AJ; Kulkarni U; Korula A; Lakshmi KM; Abraham A; Srivastava A; Mathews V
Biol Blood Marrow Transplant; 2018 Mar; 24(3):494-500. PubMed ID: 29100905
[TBL] [Abstract][Full Text] [Related]
38. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus Umbilical Cord Blood Transplantation in Adult Patients with Aplastic Anemia.
Onishi Y; Mori T; Yamazaki H; Hiramoto N; Zaimoku Y; Kanaya M; Matsue K; Onizuka M; Aotsuka N; Uchida N; Onodera K; Kanda J; Nakamae H; Yamamoto R; Kuriyama T; Kimura T; Ichinohe T; Atsuta Y;
Transplant Cell Ther; 2023 Dec; 29(12):766.e1-766.e8. PubMed ID: 37730121
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.
Dholaria B; Labopin M; Sanz J; Ruggeri A; Cornelissen J; Labussière-Wallet H; Blaise D; Forcade E; Chevallier P; Grassi A; Zubarovskaya L; Kuball J; Ceballos P; Ciceri F; Baron F; Savani BN; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):76. PubMed ID: 33941226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
